Supporting Information

Transcription

1 Supporting Information H 2 O 2 -Activatable and O 2 -Evolving Nanoparticles for Highly Efficient and Selective Photodynamic Therapy against Hypoxic Tumor Cells Huachao Chen, Jiangwei Tian, Weijiang He,* and Zijian Guo* Supplementary tables and figures II.1. Table S1. Representative size, polydispersity index (PDI), and zeta potential of HAOP NPs before and after functionalization with c(rgdfk). II.2. Table S2. Representative size, PDI, and zeta potential of HAOP NPs prepared with different amount of c(rgdfk). II.3. Figure S1. Long-term-stability study of HAOP NPs in PBS or DMEM with 10% FBS. II.4. Figure S2. Ultrasound images of HAOP NPs suspended in media with H 2 O 2 at different concentrations. II.5. Figure S3. Ultrasound images of HAOP NPs incubated with H 2 O 2 for 0 24 h. II.6. Figure S4. Real-time confocal fluorescence images to display the uptake of HAOP NPs by SKOV-3 cells. II.7. Figure S5. Colocalization images of HAOP NPs in SKOV-3 cells. II.8. Figure S6. Confocal fluorescence images of (a) U87-MG cells and (b) NAC-pretreated U87-MG cells incubated with DCFDA. II.9. Figure S7. Plots of change in fluorescent intensity of 1 µm SOSG (λ ex = 488 nm, λ em = 525 nm) vs incubation time measured from the HAOP NPs in the presence or absence of 100 µm H 2 O 2, and the HAOP NPs without catalase in the presence of H 2 O 2. II.10. Figure S8. MTT assay for U87-MG cells after treatment with HAOP NPs at different concentrations in the presence (light) and absence (dark) of 635-nm irradiation. II.11. Figure S9. MTT assay for HaCaT cells after treatment with HAOP NPs at different concentrations in the presence (light) and absence (dark) of 635-nm irradiation. II.12. Figure S10. Confocal fluorescence images showing increased intracellular O 2 level after treated with HAOP NPs. II.13. Figure S11. Tumors without any treatment and corresponding H&E staining of tumor slides. II.14. Figure S12. Confocal fluorescence images of Annexin V-FITC/PI stained U87-MG cells treated with HAOP NPs (without BHQ)-mediated PDT. II.15. Figure S13. H&E stained images of tissue sections from different organs of mice after HAOP NP-mediated PDT and the age-matched healthy mice without treatment (control). II.16. Figure S14. Tumor inhibition rates of mice treated with different doses of HAOP NPs under irradiation after 3 days. S1

2 Table S1. Representative size, PDI, and zeta potential of HAOP NPs before and after functionalization with c(rgdfk). Size (nm) Size distribution (intensity) PDI Zeta potential (mv) HAOP NPs (without RGD) HAOP NPs S2

3 Table S2. Representative size, PDI, and zeta potential of HAOP NPs prepared with different amount of c(rgdfk). crgd a b crgd Zeta potential Size c (nm) PDI c,d (%, w/w) a (%, w/w) a (mv) a c(rgdfk) added with respect to the polymer weight. b c(rgdfk) yield with respect to the polymer weight. c Determined by dynamic light scattering (DLS). d PDI, polydispersity index. Figure S1. Long-term-stability study of HAOP NPs in PBS or DMEM with 10% FBS. Figure S2. Ultrasound images of HAOP NPs suspended in media with H 2 O 2 at different concentrations. S3

4 Figure S3. Ultrasound images of HAOP NPs incubated with 100 µm H 2 O 2 for 0 24 h. Figure S4. Real-time confocal fluorescence images to display the uptake of HAOP NPs by SKOV-3 cells. The cells were incubated with HAOP NPs (50 µg ml 1 ) for 1 3 h. Figure S5. Colocalization images of HAOP NPs in SKOV-3 cells. The cells were incubated with the HAOP NPs (50 µg ml 1 ) for 3 h and then incubated with 100 nm LysoTracker Red or MitoTracker Red for 10 min. Scale bars: 20 µm. S4

5 Figure S6. Confocal fluorescence images of (a) U87-MG cells and (b) NAC-pretreated U87-MG cells incubated with DCFDA, (b) and (d) represent the bright field images of (a) and (c) respectively. Figure S7. Plots of change in fluorescent intensity of 1 µm SOSG (λ ex = 488 nm, λ em = 525 nm) vs incubation time measured from HAOP NPs in the presence or absence of 100 µm H 2 O 2, and the HAOP NPs (without catalase) in the presence of H 2 O 2. The fluorescent intensity of SOSG was measured after 635-nm irradiation at a power of 100 mw cm 2 for 5 min. S5

6 Figure S8. MTT assay for U87-MG cells after treatment with HAOP NPs at different concentrations in the presence (light) and absence (dark) of 635-nm irradiation. Figure S9. MTT assay for HaCaT cells after treatment with HAOP NPs at different concentrations in the presence (light) and absence (dark) of 635-nm irradiation. S6

7 Figure S10. Confocal fluorescence images showing increased intracellular O 2 level after treated with HAOP NPs. U87-MG cells incubated with 5 µm [Ru(dpp) 3 ]Cl 2 for 4 h, followed by incubation with the HAOP NPs for (a) 0 h, (b) 8 h, (c) 16 h and (d) 24 h. (e)-(h) represent the bright field images of (a)-(d) respectively. Scale bars: 20 µm. Figure S11. Tumors without any treatment and corresponding H&E staining of tumor slides. Scale bar: 100 µm. Figure S12. Confocal fluorescence images of Annexin V-FITC/PI stained U87-MG cells treated with HAOP NPs (without BHQ)-mediated PDT. Scale bars: 20 µm. S7

8 Figure S13. H&E stained images of tissue sections from different organs of mice after HAOP NP-mediated PDT and the age-matched healthy mice without treatment (control). Scale bars: 100 µm. Figure S14. Tumor inhibition rates of mice treated with different doses of HAOP NPs under irradiation after 3 days. High therapeutic efficacy and low systemic toxic side effects are key factors to be considered when choosing the dose of NPs. The tumor inhibition rate increased with the dose of HAOP NPs and the therapeutic efficacy reached optimum at a dose of 10 mg kg 1. S8